EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

Mazen Noureddin, Mary E Rinella, Naga P Chalasani, Guy W Neff, K Jean Lucas, Manuel E Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen C Chan, Erik J Tillman iD und 7 weitere

New England Journal of Medicine · 26.06.2025 · 392 (24) · 2413-2424

DOI: 10.1056/nejmoa2502242 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 26.06.2025. Verfasst von Mazen Noureddin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, Houston. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Antifibrotic Agents. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Akero Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsLiver CirrhosisNon-alcoholic Fatty Liver DiseaseAntifibrotic AgentsAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodInjections, SubcutaneousLiverSeverity of Illness IndexBiopsyElasticity Imaging Techniques

Substanzen

Fibroblast Growth FactorsFGF21 protein, humanAntifibrotic Agents

Autor:innen und Institutionen

  • Houston Methodist Hospital, Houston.
  • Houston Research Institute, Houston.
  • University of Chicago Pritzker School of Medicine, Chicago.
  • Indiana University School of Medicine, Indianapolis.
  • Covenant Metabolic Specialists, Fort Myers, FL.
  • Lucas Research, Morehead City, NC.

ORCID-Profile: Erik J Tillman, Reshma Shringarpure

Förderung

  • Akero Therapeutics

Zitieren

APA

Noureddin, M., Rinella, M. E., Chalasani, N. P., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C., Burch, M., Chan, D. C., Tillman, E. J., Zari, A., de Temple, B., Shringarpure, R., Jain, M., Rolph, T., Cheng, A., & Yale, K. (2025). Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. New England Journal of Medicine, 392(24), 2413-2424. https://doi.org/10.1056/nejmoa2502242

Vancouver

Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. New England Journal of Medicine. 2025;392(24):2413-2424. doi:10.1056/nejmoa2502242

BibTeX
@article{Noureddin2025,
  author = {Noureddin, Mazen and Rinella, Mary E and Chalasani, Naga P and Neff, Guy W and Lucas, K Jean and Rodriguez, Manuel E and Rudraraju, Madhavi and Patil, Rashmee and Behling, Cynthia and Burch, Mark and Chan, Doreen C and Tillman, Erik J and Zari, Arian and de Temple, Brittany and Shringarpure, Reshma and Jain, Meena and Rolph, Timothy and Cheng, Andrew and Yale, Kitty},
  title = {Efruxifermin in Compensated Liver Cirrhosis Caused by MASH},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {24},
  pages = {2413--2424},
  doi = {10.1056/nejmoa2502242}
}
Kostenlos starten →